177 related articles for article (PubMed ID: 23287011)
21. Smad7 in TGF-beta-mediated negative regulation of gut inflammation.
Monteleone G; Pallone F; MacDonald TT
Trends Immunol; 2004 Oct; 25(10):513-7. PubMed ID: 15364052
[TBL] [Abstract][Full Text] [Related]
22. Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer.
Stolfi C; Troncone E; Marafini I; Monteleone G
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33375423
[TBL] [Abstract][Full Text] [Related]
23. Antisense approach to inflammatory bowel disease: prospects and challenges.
Marafini I; Di Fusco D; Calabrese E; Sedda S; Pallone F; Monteleone G
Drugs; 2015 May; 75(7):723-30. PubMed ID: 25911184
[TBL] [Abstract][Full Text] [Related]
24. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression.
Fantini MC; Rizzo A; Fina D; Caruso R; Sarra M; Stolfi C; Becker C; Macdonald TT; Pallone F; Neurath MF; Monteleone G
Gastroenterology; 2009 Apr; 136(4):1308-16, e1-3. PubMed ID: 19192480
[TBL] [Abstract][Full Text] [Related]
25. Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Monteleone G; Stolfi C; Marafini I; Atreya R; Neurath MF
Mol Diagn Ther; 2022 Sep; 26(5):477-481. PubMed ID: 35841457
[TBL] [Abstract][Full Text] [Related]
26. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
Marafini I; Monteleone I; Dinallo V; Di Fusco D; De Simone V; Laudisi F; Fantini MC; Di Sabatino A; Pallone F; Monteleone G
J Crohns Colitis; 2017 May; 11(5):603-609. PubMed ID: 28453765
[TBL] [Abstract][Full Text] [Related]
27. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F
N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease.
Benahmed M; Meresse B; Arnulf B; Barbe U; Mention JJ; Verkarre V; Allez M; Cellier C; Hermine O; Cerf-Bensussan N
Gastroenterology; 2007 Mar; 132(3):994-1008. PubMed ID: 17324400
[TBL] [Abstract][Full Text] [Related]
29. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7.
Wang W; Huang XR; Li AG; Liu F; Li JH; Truong LD; Wang XJ; Lan HY
J Am Soc Nephrol; 2005 May; 16(5):1371-83. PubMed ID: 15788474
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.
Monteleone G; Fantini MC; Onali S; Zorzi F; Sancesario G; Bernardini S; Calabrese E; Viti F; Monteleone I; Biancone L; Pallone F
Mol Ther; 2012 Apr; 20(4):870-6. PubMed ID: 22252452
[TBL] [Abstract][Full Text] [Related]
31. Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.
Tang Y; Reissig S; Glasmacher E; Regen T; Wanke F; Nikolaev A; Gerlach K; Popp V; Karram K; Fantini MC; Schattenberg JM; Galle PR; Neurath MF; Weigmann B; Kurschus FC; Hövelmeyer N; Waisman A
Gastroenterology; 2019 Feb; 156(3):692-707.e7. PubMed ID: 30315770
[TBL] [Abstract][Full Text] [Related]
32. Roles of Smad3 and Smad7 in rat pancreatic stellate cells activated by transforming growth factor-beta 1.
Qian ZY; Peng Q; Zhang ZW; Zhou LA; Miao Y
Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):531-6. PubMed ID: 20943464
[TBL] [Abstract][Full Text] [Related]
33. Novel Targeted Therapies for Inflammatory Bowel Disease.
Coskun M; Vermeire S; Nielsen OH
Trends Pharmacol Sci; 2017 Feb; 38(2):127-142. PubMed ID: 27916280
[TBL] [Abstract][Full Text] [Related]
34. [Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Miao Y; Zhang W; Zhong M; Ma X; Qi TG; Sun H
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):366-70. PubMed ID: 17456374
[TBL] [Abstract][Full Text] [Related]
35. Attenuated TGF-β1 responsiveness of dendritic cells and their precursors in atopic dermatitis.
Peng WM; Maintz L; Allam JP; Novak N
Eur J Immunol; 2013 May; 43(5):1374-82. PubMed ID: 23436698
[TBL] [Abstract][Full Text] [Related]
36. Smad7 as a positive regulator of intestinal inflammatory diseases.
Monteleone G; Laudisi F; Stolfi C
Curr Res Immunol; 2023; 4():100055. PubMed ID: 36714553
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor-β/Smad signalling in diabetic nephropathy.
Lan HY
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842
[TBL] [Abstract][Full Text] [Related]
38. Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7.
Inamoto S; Iwata S; Inamoto T; Nomura S; Sasaki T; Urasaki Y; Hosono O; Kawasaki H; Tanaka H; Dang NH; Morimoto C
Oncogene; 2007 Feb; 26(6):893-904. PubMed ID: 16909115
[TBL] [Abstract][Full Text] [Related]
39. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Smad7, a negative regulator of TGF-beta signaling, suppresses autoimmune encephalomyelitis.
Kleiter I; Pedré X; Mueller AM; Poeschl P; Couillard-Despres S; Spruss T; Bogdahn U; Giegerich G; Steinbrecher A
J Neuroimmunol; 2007 Jul; 187(1-2):61-73. PubMed ID: 17553571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
